Multisystem Inflammatory Syndrome is NOT Exclusive to COVID-19
No, multisystem inflammatory syndrome does not occur only with COVID-19, though MIS-C/MIS-A as currently defined is specifically linked to SARS-CoV-2 infection. The critical distinction is that similar hyperinflammatory syndromes have always existed—Kawasaki disease, toxic shock syndrome, and other infection-triggered inflammatory conditions—but the specific entity we now call MIS-C/MIS-A emerged during the COVID-19 pandemic and requires evidence of SARS-CoV-2 exposure for diagnosis 1.
The Diagnostic Reality
The ACR guidelines explicitly acknowledge that "clinical features of MIS-C may also be seen in other types of infections and malignant entities and in other rheumatic diseases in childhood" 1. This is a crucial clinical pitfall: the syndrome's presentation overlaps substantially with pre-existing conditions, making SARS-CoV-2 exposure the defining feature rather than unique clinical characteristics.
What Makes MIS-C/MIS-A "COVID-Specific"
All major case definitions (CDC, WHO, RCPCH) require:
- Evidence of SARS-CoV-2 infection (positive PCR, serology, antigen test, or documented exposure within 4 weeks) 2
- Exclusion of other microbial causes
- Temporal association with COVID-19 (typically 2-6 weeks post-infection) 1
Without SARS-CoV-2 exposure, the same clinical presentation would be classified as Kawasaki disease, toxic shock syndrome, macrophage activation syndrome, or another hyperinflammatory condition 3.
The Broader Context: Infection-Triggered Hyperinflammation
Recent evidence suggests MIS-C may actually represent SARS-CoV-2-triggered Kawasaki disease rather than a truly novel syndrome 4. This 2026 study found that:
- KD was the most common phenotype across all SARS-CoV-2 variants
- Countries with high pre-pandemic KD incidence did not identify MIS-C as a "new" syndrome
- Clinical phenotype stratification outperformed MIS-C case definitions
This supports a pathogen-agnostic approach to post-infectious hyperinflammation, recognizing that multiple pathogens can trigger similar immune dysregulation 4.
Clinical Implications
When Evaluating a Patient with Suspected MIS:
Document SARS-CoV-2 exposure status definitively
- PCR (may be negative by presentation time)
- Serology (more sensitive for delayed presentation)
- Exposure history within 4 weeks 2
Rule out alternative infections aggressively
- The guidelines emphasize this is mandatory, not optional 1
- Other viral, bacterial, and fungal pathogens can cause identical presentations
Recognize the phenotypic spectrum
- Shock-predominant
- Kawasaki disease-like
- Fever with hyperinflammation 4
The Diagnostic Pitfall
Do not assume every child with fever, inflammation, and multiorgan involvement during or after the pandemic has MIS-C. The ACR specifically warns that "a child 'under investigation' for MIS-C should also be evaluated for other possible infections and non-infection-related conditions" 2. This is critical because treatment approaches differ, and missing an alternative diagnosis (particularly bacterial sepsis or malignancy) carries significant mortality risk.
MIS-A: The Adult Presentation
MIS-A is increasingly recognized in adults with similar pathophysiology 5, 6, 7, 8. Key differences from pediatric disease:
- Higher mortality risk compared to other inflammatory conditions 5
- Sex-specific patterns: women have more respiratory involvement, men more cardiac complications 5
- Often occurs after asymptomatic or mild COVID-19 7, 8
The same principle applies: MIS-A requires documented SARS-CoV-2 exposure, but the hyperinflammatory response itself is not unique to COVID-19 5.
The Bottom Line for Clinical Practice
Think of MIS-C/MIS-A as SARS-CoV-2's specific trigger for a broader category of post-infectious hyperinflammatory syndromes. Other pathogens trigger similar responses (hence Kawasaki disease existed long before COVID-19), but we reserve the MIS terminology specifically for SARS-CoV-2-associated cases. This naming convention reflects epidemiology and public health tracking rather than a fundamentally unique disease mechanism 4.
Always maintain diagnostic vigilance for alternative causes, particularly in patients without clear SARS-CoV-2 exposure, as the treatment and prognosis may differ substantially 1, 2.